• About us
• Contact

Advertisement

Person › Details

Krzysztof Brzózka (Selvita S.A. (WSE:SLV))

Brzózka, Krzysztof (Selvita 201511 CSO)

 

	Organisation	Selvita S.A. (WSE:SLV)
	Group	Selvita (Group)
	Product	drug discovery services
	Product 2	drug discovery

Record changed: 2022-07-08

Advertisement

More documents for Krzysztof Brzózka

• [1] Ryvu Therapeutics S.A.. (7/7/22). "Press Release: Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies". Alameda, CA & Krakow....
• [2] Selvita S.A.. (8/8/17). "Press Release: Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients". Krakow & Rye Brook....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.